Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly
- 11 March 2019
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 37 (15), 2051-2056
- https://doi.org/10.1016/j.vaccine.2019.03.002
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studiesThe Lancet Infectious Diseases, 2016
- Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness studyBMC Medicine, 2015
- Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjectsVaccine, 2014
- The burden of influenza in England by age and clinical risk group: A statistical analysis to inform vaccine policyJournal of Infection, 2014
- The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderlyVaccine, 2013
- Assessing Optimal Target Populations for Influenza Vaccination Programmes: An Evidence Synthesis and Modelling StudyPLoS Medicine, 2013
- Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission modelVaccine, 2013
- Cost-Effectiveness of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Adult Hemodialysis PatientsAmerican Journal of Kidney Diseases, 2011
- Social Contacts and Mixing Patterns Relevant to the Spread of Infectious DiseasesPLoS Medicine, 2008
- Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderlyVaccine, 1999